Log in to save to my catalogue

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-C...

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-C...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2508532239

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

Publication information

Publisher

Cold Spring Harbor: Cold Spring Harbor Laboratory Press

More information

Scope and Contents

Contents

Abstract There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold...

Alternative Titles

Full title

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2508532239

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2508532239

Other Identifiers

ISSN

2692-8205

E-ISSN

2692-8205

DOI

10.1101/2020.08.31.274639

How to access this item